A Phase 1 Study Evaluating the Safety and Pharmacokinetics of ABT-348 in Subjects With Advanced Hematologic Malignancies

Status
Active
Cancer Type
Leukemia
Trial Phase
Phase I
Eligibility
18 and over, Male and Female
Study Type
Biomarker/Laboratory analysis
Treatment
NCD ID
NCT01110473
Protocol IDs
M10-943 (primary)
Study Sponsor
Abbott Laboratories

Summary

The purpose of this study is to determine the safety, pharmacokinetics, and maximum tolerated dose of ABT-348 as monotherapy

Objectives

The primary objectives of this study are to determine safety and pharmacokinetics of ABT-348.

The secondary objectives are to determine the maximum tolerated dose and recommended Phase 2 dose of ABT-348 when administered as a monotherapy in subjects with advanced hematologic malignancies.

Treatment Sites in Georgia


Winship Cancer Institute of Emory University
1365 Clifton Road NE
Building C
Atlanta, GA 30322
404-778-5180
winshipcancer.emory.edu

Study Coordinator:
Beverly Bryan
404-778-4994

Doctors:

Martha L. Arellano MD
H. Jean Khoury MD, FACP
Morgan L. McLemore MD
Elliott F. Winton MD